vs
Anika Therapeutics, Inc.（ANIK）与ARTIVION, INC.（AORT）财务数据对比。点击上方公司名可切换其他公司
ARTIVION, INC.的季度营收约是Anika Therapeutics, Inc.的3.8倍（$116.0M vs $30.6M）。ARTIVION, INC.净利率更高（2.1% vs 1.0%，领先1.1%）。ARTIVION, INC.同比增速更快（19.2% vs 0.0%）。Anika Therapeutics, Inc.自由现金流更多（$4.0M vs $-7.9M）。过去两年ARTIVION, INC.的营收复合增速更高（9.1% vs 2.7%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
ANIK vs AORT — 直观对比
营收规模更大
AORT
是对方的3.8倍
$30.6M
营收增速更快
AORT
高出19.2%
0.0%
净利率更高
AORT
高出1.1%
1.0%
自由现金流更多
ANIK
多$11.9M
$-7.9M
两年增速更快
AORT
近两年复合增速
2.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $30.6M | $116.0M |
| 净利润 | $292.0K | $2.4M |
| 毛利率 | 62.6% | 63.1% |
| 营业利润率 | 2.1% | 9.2% |
| 净利率 | 1.0% | 2.1% |
| 营收同比 | 0.0% | 19.2% |
| 净利润同比 | 101.3% | 114.7% |
| 每股收益（稀释后） | $0.02 | $0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIKAORT
| Q4 25 | $30.6M | $116.0M | ||
| Q3 25 | $27.8M | $113.4M | ||
| Q2 25 | $28.2M | $113.0M | ||
| Q1 25 | $26.2M | $99.0M | ||
| Q4 24 | $30.6M | $97.3M | ||
| Q3 24 | $29.6M | $95.8M | ||
| Q2 24 | $30.7M | $98.0M | ||
| Q1 24 | $29.0M | $97.4M |
净利润ANIKAORT
| Q4 25 | $292.0K | $2.4M | ||
| Q3 25 | $-2.3M | $6.5M | ||
| Q2 25 | $-4.0M | $1.3M | ||
| Q1 25 | $-4.9M | $-505.0K | ||
| Q4 24 | $-21.9M | $-16.5M | ||
| Q3 24 | $-29.9M | $-2.3M | ||
| Q2 24 | $-88.0K | $-2.1M | ||
| Q1 24 | $-4.5M | $7.5M |
毛利率ANIKAORT
| Q4 25 | 62.6% | 63.1% | ||
| Q3 25 | 56.0% | 65.6% | ||
| Q2 25 | 50.9% | 64.7% | ||
| Q1 25 | 56.1% | 64.2% | ||
| Q4 24 | 56.0% | 63.2% | ||
| Q3 24 | 65.7% | 63.7% | ||
| Q2 24 | 66.7% | 64.6% | ||
| Q1 24 | 65.4% | 64.6% |
营业利润率ANIKAORT
| Q4 25 | 2.1% | 9.2% | ||
| Q3 25 | -11.6% | 11.1% | ||
| Q2 25 | -14.8% | 7.4% | ||
| Q1 25 | -16.4% | 2.2% | ||
| Q4 24 | -2.3% | 2.7% | ||
| Q3 24 | -0.3% | 4.6% | ||
| Q2 24 | -5.9% | 6.6% | ||
| Q1 24 | -8.6% | 26.0% |
净利率ANIKAORT
| Q4 25 | 1.0% | 2.1% | ||
| Q3 25 | -8.4% | 5.7% | ||
| Q2 25 | -14.1% | 1.2% | ||
| Q1 25 | -18.6% | -0.5% | ||
| Q4 24 | -71.4% | -16.9% | ||
| Q3 24 | -101.2% | -2.4% | ||
| Q2 24 | -0.3% | -2.2% | ||
| Q1 24 | -15.6% | 7.7% |
每股收益（稀释后）ANIKAORT
| Q4 25 | $0.02 | $0.06 | ||
| Q3 25 | $-0.16 | $0.13 | ||
| Q2 25 | $-0.28 | $0.03 | ||
| Q1 25 | $-0.34 | $-0.01 | ||
| Q4 24 | $-1.49 | $-0.40 | ||
| Q3 24 | $-2.03 | $-0.05 | ||
| Q2 24 | $0.00 | $-0.05 | ||
| Q1 24 | $-0.31 | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $81.2M | $64.9M |
| 总债务越低越好 | — | $215.1M |
| 股东权益账面价值 | $143.5M | $448.2M |
| 总资产 | $190.3M | $884.8M |
| 负债/权益比越低杠杆越低 | — | 0.48× |
8季度趋势，按日历期对齐
现金及短期投资ANIKAORT
| Q4 25 | $81.2M | $64.9M | ||
| Q3 25 | $80.2M | $73.4M | ||
| Q2 25 | $77.1M | $53.5M | ||
| Q1 25 | $75.4M | $37.7M | ||
| Q4 24 | $79.2M | $53.5M | ||
| Q3 24 | $90.7M | $56.2M | ||
| Q2 24 | $96.6M | $55.0M | ||
| Q1 24 | $100.7M | $51.1M |
总债务ANIKAORT
| Q4 25 | — | $215.1M | ||
| Q3 25 | — | $214.9M | ||
| Q2 25 | — | $215.6M | ||
| Q1 25 | — | $314.7M | ||
| Q4 24 | — | $314.3M | ||
| Q3 24 | — | $314.0M | ||
| Q2 24 | — | $313.6M | ||
| Q1 24 | — | $313.3M |
股东权益ANIKAORT
| Q4 25 | $143.5M | $448.2M | ||
| Q3 25 | $146.8M | $438.7M | ||
| Q2 25 | $147.7M | $419.9M | ||
| Q1 25 | $148.4M | $294.3M | ||
| Q4 24 | $154.0M | $276.2M | ||
| Q3 24 | $179.9M | $304.7M | ||
| Q2 24 | $210.3M | $295.1M | ||
| Q1 24 | $208.5M | $295.0M |
总资产ANIKAORT
| Q4 25 | $190.3M | $884.8M | ||
| Q3 25 | $189.4M | $857.7M | ||
| Q2 25 | $187.7M | $838.4M | ||
| Q1 25 | $190.6M | $791.2M | ||
| Q4 24 | $202.7M | $789.1M | ||
| Q3 24 | $231.4M | $803.1M | ||
| Q2 24 | $262.7M | $789.5M | ||
| Q1 24 | $263.7M | $784.0M |
负债/权益比ANIKAORT
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.49× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 1.07× | ||
| Q4 24 | — | 1.14× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.06× | ||
| Q1 24 | — | 1.06× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.6M | $19.6M |
| 自由现金流经营现金流 - 资本支出 | $4.0M | $-7.9M |
| 自由现金流率自由现金流/营收 | 13.0% | -6.9% |
| 资本支出强度资本支出/营收 | 2.1% | 23.7% |
| 现金转化率经营现金流/净利润 | 15.88× | 8.06× |
| 过去12个月自由现金流最近4个季度 | $4.4M | $839.0K |
8季度趋势，按日历期对齐
经营现金流ANIKAORT
| Q4 25 | $4.6M | $19.6M | ||
| Q3 25 | $6.9M | $22.3M | ||
| Q2 25 | $-189.0K | $15.0M | ||
| Q1 25 | $-130.0K | $-17.0M | ||
| Q4 24 | $1.6M | $10.1M | ||
| Q3 24 | $5.0M | $11.5M | ||
| Q2 24 | $-1.1M | $6.1M | ||
| Q1 24 | $-126.0K | $-5.5M |
自由现金流ANIKAORT
| Q4 25 | $4.0M | $-7.9M | ||
| Q3 25 | $5.0M | $17.7M | ||
| Q2 25 | $-1.7M | $11.7M | ||
| Q1 25 | $-3.0M | $-20.6M | ||
| Q4 24 | $275.0K | $8.7M | ||
| Q3 24 | $3.8M | $7.8M | ||
| Q2 24 | $-4.5M | $3.6M | ||
| Q1 24 | $-1.9M | $-9.1M |
自由现金流率ANIKAORT
| Q4 25 | 13.0% | -6.9% | ||
| Q3 25 | 17.9% | 15.6% | ||
| Q2 25 | -5.9% | 10.4% | ||
| Q1 25 | -11.3% | -20.8% | ||
| Q4 24 | 0.9% | 9.0% | ||
| Q3 24 | 12.9% | 8.2% | ||
| Q2 24 | -14.6% | 3.7% | ||
| Q1 24 | -6.7% | -9.3% |
资本支出强度ANIKAORT
| Q4 25 | 2.1% | 23.7% | ||
| Q3 25 | 6.8% | 4.1% | ||
| Q2 25 | 5.2% | 2.9% | ||
| Q1 25 | 10.8% | 3.7% | ||
| Q4 24 | 4.3% | 1.5% | ||
| Q3 24 | 4.1% | 3.8% | ||
| Q2 24 | 11.1% | 2.6% | ||
| Q1 24 | 6.2% | 3.7% |
现金转化率ANIKAORT
| Q4 25 | 15.88× | 8.06× | ||
| Q3 25 | — | 3.42× | ||
| Q2 25 | — | 11.16× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.73× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIK
| OEM Channel | $17.3M | 57% |
| Commercial Channel | $13.3M | 43% |
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
